BioSpace News Archive

Imago BioSciences, Inc., a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, announced that executive leadership will be participating in the following upcoming investor conferences:

OPTEC International, Inc., a developer of UV and UV-C safety products using related advanced technologies specific to Personal Protection Equipment, announced the addition of Antigen & Antibody Rapid-Test Kits with highly accurate results in 10 Minutes to the company’s PPE Inventory for global distribution.

Evolve Biologics Inc. (“Evolve”), an innovative plasma-derived therapeutics company, today announced that it has successfully completed its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”), conducted at 12 study centers across the U.S. and Canada.

Milestone Scientific Inc. (NYSE American:MLSS) , a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has signed two additional distribution agreements with Atlanta Dental and Nashville Dental for its Wand® Single Tooth Anesthesia (STA) System. Atlanta Dental and Nashville Dental

Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, announced results from its MELT Phase 1 study, a comparative bioavailability study with the objective of characterizing the pharmacokinetic parameters of two dosage strengths of the patented MELT technology (midazolam 3 mg/ketamine 25 mg and midazolam 6 mg/ketamine 50 mg) in healthy volunteers

Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that a scientific manuscript titled: “ Targeting G542X CFTR Nonsense Alleles With ELX-02 Restores CFTR Function in Human-Derived Intestinal Organoids ” was p

- US$100 million in milestone payments including US$20 million upfront, as well as a double-digit royalty - Nuance’s business model, commercial acumen and collaborative approach considered an ideal fit for Antibe

Results from the study assessing concordance of genomic alterations identified by liquid and tissue biopsy published in Clinical Cancer Research and to be presented at the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium

Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing of drug products, announced today that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its early liver cancer screening research results were cited by the “Chinese Anti-Cancer Association Guidelines for Patients with Primary Liver Cancer”